Correlation Between Amerco and Crispr Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Amerco and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amerco and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Amerco and Crispr Therapeutics AG, you can compare the effects of market volatilities on Amerco and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amerco with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amerco and Crispr Therapeutics.

Diversification Opportunities for Amerco and Crispr Therapeutics

-0.41
  Correlation Coefficient

Very good diversification

The 3 months correlation between Amerco and Crispr is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Amerco and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Amerco is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amerco are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Amerco i.e., Amerco and Crispr Therapeutics go up and down completely randomly.

Pair Corralation between Amerco and Crispr Therapeutics

Given the investment horizon of 90 days Amerco is expected to generate 0.46 times more return on investment than Crispr Therapeutics. However, Amerco is 2.16 times less risky than Crispr Therapeutics. It trades about 0.0 of its potential returns per unit of risk. Crispr Therapeutics AG is currently generating about -0.01 per unit of risk. If you would invest  7,040  in Amerco on September 6, 2022 and sell it today you would lose (429.00)  from holding Amerco or give up 6.09% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Amerco  vs.  Crispr Therapeutics AG

 Performance (%) 
       Timeline  
Amerco 
Amerco Performance
12 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Amerco are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Even with relatively conflicting basic indicators, Amerco revealed solid returns over the last few months and may actually be approaching a breakup point.

Amerco Price Channel

Crispr Therapeutics 
Crispr Performance
0 of 100
Over the last 90 days Crispr Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm insiders.

Crispr Price Channel

Amerco and Crispr Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Amerco and Crispr Therapeutics

The main advantage of trading using opposite Amerco and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amerco position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.
Amerco vs. Aarons Inc
Amerco vs. AerCap Holdings NV
Amerco vs. Air Lease
Amerco vs. FlexShopper
The idea behind Amerco and Crispr Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Crispr Therapeutics vs. Aurora Cannabis
Crispr Therapeutics vs. Agilent Technologies
Crispr Therapeutics vs. Acer Therapeutics
Check out your portfolio center. Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Other Complementary Tools

Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go